Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q2 2023 Pharma Services Update

Skip to the end of the Expertise Menu

Q2 2023 Pharma Services Update

Despite an uncertain macroeconomic environment, recessionary fears, and the impact of tightening credit markets, M&A activity in pharma services displayed strong resiliency in Q2-23, fueled by platform investments and dozens of add-on acquisitions. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including R&D funding, reducing costs, technological advancements, and access to value-added specialty services. Certain therapeutic areas, oncology and CNS diseases for example, will likely remain popular due to a robust pipeline of R&D activity.

Provident expects M&A activity to rebound in the second half of 2023 as companies look to fill the potential growth gap from the $100B in patents set to expire by 2030.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/07/Q2-2023-Newsletter-Package_Pharma-Services.pdf” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]